← board
LIPO
Lipella Pharmaceuticals, Inc.distress 6/10 · elevated risk$0.030%today-96% from 52w high
Lead: Oral Lichen Planus
Revenue
pre-revenue
Liquidity
$2M
Runway
0.5 yrs
Shares 1y
0%
Price & events
-81.0% over 6M
CatalystRating changeDilutionFinancingdashed = today
+0.0%
1D
-49.2%
1W
-58.7%
1M
+65.0%
3M
-81.0%
6M
-95.5%
1Y
-99.1%
2Y
—
5Y
-99.9%
All
Overview
- Market Cap
- $152.49K
- Volume
- 0
- 52 Week Range
- $0.02 – $0.83
- Total Shares
- 4.62M
- Float Shares
- 4.33M
- Short %
- 2.35%
- % Held by Insiders
- 6.31%
- % Held by Institutions
- 1.30%
- Beta
- 1.37
Pipeline stages · 1 programs
LP-10 (Liposomal Tacrolimus)
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Pipeline · 1 trials · 0 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| 2025-06-01 | Phase 2 | LP-10 (Liposomal Tacrolimus) | Oral Lichen Planus | 24 | active not recruiting |
Catalyst news & presentations · 5
- second half of 2025readoutPhase 2LP-310 · Final topline data from Phase 2a trialSEC 8-K
- second quarter of 2025readoutPhase 2LP-310 · Final topline data from fully enrolled Phase 2a trial.SEC 8-K
- 2025-06-20withdrawalDelisting from Nasdaq Capital Market due to non-compliance with Listing Rules 5100, 5635, and 5640.SEC 8-K
- during the BIO CEO & Investor Conference on February 11, 2025conferencedata presentationsecondaryPhase 2LP-310 · Positive topline Phase 2a results presented at BIO CEO & Investor ConferenceSEC 8-K
- 2025-02-06fda agreementLP-310 · FDA approved Expanded Access Program for LP-310 in oral lichen planusSEC 8-K
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
no consensus
- no recent rating changes
Competitors — Oral Lichen Planus
- none identified
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.